LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis

Fangjing Zhong\(^3\), Sheng Liu\(^2\), Donghai Hu\(^1\), Liwen Chen\(^1\)*

1. Department of Anesthesiology, Hubei Cancer Hospital, Wuhan 430079, China
2. Department of Hepatobiliary Surgery, Hubei Cancer Hospital, Wuhan 430079, China
3. Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha 410000, Hunan, China

*Corresponding author: Liwen Chen, chenliwen199106@163.com. Department of Anesthesiology, Hubei Cancer Hospital, Wuhan 430079, China

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2021.08.15; Accepted: 2021.12.20; Published: 2022.01.04

Abstract

**Background:** LncRNA is a key factor influencing tumor development. The present study aimed to investigate the effect of a novel lncRNA on the progression of hepatocellular carcinoma (HCC).

**Methods:** A candidate lncRNA in The Cancer Genome Atlas database was identified using limma and survival R packages. The effect of lncRNA AC099850.3 on cell proliferation, apoptosis, migration, and invasion, as well as its association with immune cells in HCC were investigated. Furthermore, the functional mechanisms of lncRNA AC099850.3 in HCC were elucidated.

**Results:** The aberrant expression of lncRNA AC099850.3 was identified in tumor tissues and its prognostic relevance in HCC was determined. The results revealed that AC099850.3 was highly expressed in HCC tissues and cell lines, and it predicted poor prognosis in patients with HCC. Furthermore, knockdown of AC099850.3 significantly suppressed the proliferation and metastatic potential of HCC cells, and promoted cell apoptosis in HCC cells. The results of gene set enrichment analysis revealed that the PI3K/AKT pathway was associated with the biological function of AC099850.3, which was further validated by western blotting. PRR11 was identified as the target gene of AC099850.3 and we established that AC099850.3 acted as an oncogene in the PRR11/PI3K/AKT axis. Immune cell infiltration analyses revealed that AC099850.3 was positively correlated with T follicular helper cells, M0 macrophages, CD4+ memory T cells, and memory B cells. Conversely, AC099850.3 was negatively correlated with M2 macrophages, monocytes, natural killer cells, and CD8+ T cells, which could be responsible for its oncogenic effect. Of note, a significantly positive correlation was observed between AC099850.3 and key immune checkpoint molecules (PD-1, PD-L1, PD-L2, and CTLA4) in the present study, making AC099850.3 a potential immune therapeutic target for HCC.

**Conclusion:** AC099850.3 can promote malignant biological behavior of HCC cells, and could be a potential biomarker and therapeutic target for HCC.

Key words: LncRNA, AC099850.3, hepatocellular carcinoma, PRR11, PI3K/AKT, tumor immunity

Introduction

Liver cancer is one of the most prevalent malignant tumors and the third leading cause of cancer-related death worldwide. The ten-year survival rate of liver cancer is approximately 20% [1]. Based on the pathological subtypes, hepatocellular carcinoma (HCC) is the most widespread subtype of liver cancer and accounts for approximately 90% cases [2]. Chronic hepatitis remains the leading cause of HCC and most patients with HCC are often diagnosed at advanced stages due to lack of early
symptoms [3]. Hepatectomy is an effective approach for the treatment of patients with HCC. However, high rates of postoperative metastasis and recurrence, as well as liver function reserve of patients with advanced stage HCC are still some of the clinical challenges associated with poor prognosis [4, 5], which highlights the importance of developing a novel therapeutic strategy. Currently, molecular targeted therapy has shown a promising prospect in tumor therapy and prognosis improvement.

Long non-coding RNAs (LncRNAs) are a type of non-coding RNAs with lengths exceeding 200 nucleotides and they can influence the maturity of human cells, metabolic states, and physical conditions [6]. LncRNAs primarily serve as regulators in human cells and function by regulating the downstream genes and proteins [7]. In addition, increasing attention has been focused on the underlying association between lncRNAs and malignant tumors. For example, Lian et al. identified a novel lncRNA LINC00460 in colorectal cancer, which facilitated cell proliferation and inhibited apoptosis by regulating KLF2 and CUL4A [8]. Li et al. demonstrated that the lncRNA SNHG1 could influence sorafenib resistance by activating the AKT pathway, which had the potential for clinical application [9]. Zhou et al. revealed that the LncRNA ID2-AS1 could inhibit the migration, invasion, and metastasis of HCC through the HDAC8/ID2 pathway based on in vitro and in vivo experiments [10].

Presently, the rapid development of next-generation sequencing generates massive genomic data, which facilitates the analysis of intrinsic disease mechanisms. In the current study, we first identified a prognosis-related lncRNA AC099850.3 by performing bioinformatics analysis. In vitro and in vivo experiments were further conducted to elucidate the role of AC099850.3 in HCC. The results revealed that AC099850.3 was highly expressed in HCC tissues and cell lines, and it was associated with poor prognosis in patients with HCC. AC099850.3 significantly promoted HCC cell proliferation, migration, and invasion through the PRR11/P13K/AKT pathway. Moreover, correlation analyses results revealed that AC099850.3 considerably influenced the tumor immune microenvironment of HCC and it was positively associated with the expression of immune checkpoints molecules (PD-1, PD-L1, PD-L2, and CTLA4). Immunofluorescence analysis revealed that tissues with high expression of AC099850.3 tended to have relatively low M2 macrophage infiltration levels. In summary, our results revealed that AC099850.3 could be a potential therapeutic target for HCC.

Methods

Data acquisition

The open access data used in the present study, including transcriptome data, clinical information, and information regarding prognosis of patients with hepatocellular carcinoma (TCGA-LIHC) were obtained from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/). Transcriptome data in the form of “FPKM” (Fragments per kilobase of exon model per million mapped reads) and annotated by the last reference file “GRCh38.p13.gct” were downloaded from the ENSEMBL website (http://useast.ensembl.org/index.html). The expression profiles were processed by completing missing values and normalizing data before analysis. Clinical and prognostic information of single samples were collated into a combined file using R software version 3.6.0 (The R Foundation for Statistical Computing, Vienna, Austria/ https://www.r-project.org). The patients of TCGA meeting the following criteria were included in our analysis: 1. have transcriptional profiling data; 2. have complete clinical information. The patients with incomplete clinical information and transcriptional data were excluded.

Identification of differentially expressed lncRNAs and clinical correlation analysis

Genes included in the expression profiles were separated into protein-coding and lncRNAs genes based on the gene-biotype in the reference file “GRCh38.p13.gct”. Differentially expressed lncRNAs (DElcs) were identified using limma package in R with a threshold value of |logFC|>3 and P value < 0.05. Wilcoxon test for paired samples was used to compare the differences in target lncRNAs between two groups. Survival package in R was used to analyze differences in prognosis and Kaplan–Meier survival curves were used to analyze differences between two groups.

Tissues and cell lines

HCC and adjacent normal tissue were obtained from Hubei Cancer Hospital, which were pathological confirmed. All patients provided written informed consent. Four HCC cell lines (HepG2, Hep3B, Huh7, and LM3) and one normal human hepatocyte cell line (LO2) were purchased from iCell Bioscience Inc. (Shanghai, China).

Quantitative real-time polymerase chain reaction assay

Total RNA of HCC tissues and cell lines were extracted using RNA extraction kit (Tiangen Biotech., Beijing, China) according to the manufacturer’s
instructions. Subsequently, reverse transcription was performed using FastQuant RT kit (Tiangen Biotech., Beijing, China). Polymerase chain reaction (PCR) amplicons were detected using SYBR green real-time quantitative PCR (qRT-PCR). The primers used were as follows: AC099850.3-F: 5′-CCACATGGTCAAGTAGTACGGGAC-3′; AC099850.3-R: 5′-GACAATGCGCTTGCCAAGGAAATC-3′; CD274-F: 5′-CTGCCTTGGTCATGAGTGAGTTGAAG-3′; CD274-R: 5′-CATCGTACTCCTCTCTCGCC-3′; PDCD1-F: 5′-CAACCACAGGTTTGGAACCTGG-3′; PDCD1-R: 5′-CAACCACAGGTTTGGAACCTGG-3′; CTLA4-F: 5′-CTGCCCTGGACATGATGAGTTGACC-3′; CTLA4-R: 5′-TTCAGTCCTTGGAACATCGTGAGTGTA-3′; PDCD1LG2-F: 5′-TCTCCAATGAGCCTTGAGTTGCT-3′; PDCD1LG2-R: 5′-CTGCCCTGGACATGATGAGTTGACC-3′; GAPDH-F: 5′-TCTCCAATGAGCCTTGAGTTGCT-3′; GAPDH-R: 5′-CATGCCATGGACTGTG-3′.

**Western blotting assay**

Total proteins were extracted using the total protein extraction kit (P1250; Applygen Technologies Inc., Beijing, China) and their concentrations were determined using a BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). Protein samples were initially separated using dodecyl-sulfate polyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride membranes. The polyvinylidene fluoride membranes were incubated with primary antibodies (anti-AKT, anti-p-AKT, anti-cyclin D1, and anti-GAPDH) overnight at 4 °C. Afterward, the membranes were incubated with secondary antibodies for 30 min at room temperature.

**Cell transfection assay**

Cells were transfected with Lipofectamine 2000 transfection reagent that was purchased from Invitrogen Corp (Carlsbad, CA, USA). The control and target plasmids were transfected into Hep3B and Huh7 cell lines. The target sequences of siRNAs were follows: AC099850.3-siRNA1: CTGCCTGAGACCTCCA; AC099850.3-siRNA2: CCACGCGCTTATTAGCTGAGT; AC099850.3-siRNA3: GGCCTACCATGCTCGGTA. The knockdown efficiencies were verified using qRT-PCR.

**Colony formation assay**

Colony formation assay was performed using Hep3B and Huh7 cell lines. A total of 500 cells were seeded into a six-well plate and cultured for two weeks. Culture medium was changed every four days. Cells were finally stained with crystal violet and counted.

**Cell counting kit-8 assay**

Cell proliferation/viability assay was conducted using a cell counting kit-8 (CCK-8 kit) (Dojindo, Kumamoto, Japan). Briefly, cells were resuspended in serum-free medium and then inoculated into 96-well plates at a density of 200 cells per plate. Plates were incubated at 37 °C for 2 hours and absorbance measured at a wavelength of 450 nm.

**EdU (5-Ethynyl-2-deoxyuridine) assay**

EdU assay was conducted to assess DNA synthesis in cells using the EdU assay kit (RiboBio, Guangzhou, China). Briefly, cells were incubated with EdU solution for 2 hours under the condition of 5% CO₂ and 37 °C. Thereafter, cells were fixed with 4% paraformaldehyde and protected from light. After staining with DAPI, cells were observed and photographed by fluorescence microscopy.

**Analysis of cell apoptosis using flow cytometry**

Cell apoptosis was assessed using an Annexin V-FITC/PI apoptosis kit (KeyGen Biotech, Nanjing, China). Cells were digested with trypsin without EDTA and washed three times with phosphate-buffered saline. Cells were resuspended in binding buffer and then stained with anti-Annexin V-FITC/PI. A flow cytometer was used to analyze the rate of apoptosis in cells.

**Transwell migration and invasions assays**

Transwell invasion and migration assays were performed in 24-well chambers (Corning Costar, Cambridge, MA, USA). Cells were resuspended in serum-free medium and then placed in the upper chamber with or without Matrigel. Medium (500 ul) containing 10% serum was added to the lower chambers. The invaded cells were stained with crystal violet after 24 hours.

**Wound healing assay**

Cells were seeded into six-well plates and cultured to a confluent monolayer. The confluent monolayer of cells was scratched using a 10-µl pipette tip. Cell scratches were recorded using a microscope camera at 0 and 24 hours.

**Immunofluorescence**

Immunofluorescence was used to assess the level of M2 macrophage infiltration in patients with high and low AC099850.3 expression. Tissue sections were fixed in 4% paraformaldehyde and then blocked with 2.5% goat serum at room temperature for 1 hour. Next, the sections were incubated with CD206 antibody (proteintech) overnight at 4 °C. After that, the sections were incubated with second antibody (anti-rabbit IgG) for 1 hour and with DAPI for 15 min.
at room temperature. A confocal microscope was used to perform slices photograph.

**Biological pathway and immune infiltration analyses**

Gene set enrichment analysis (GSEA) was used to identify the biological pathways associated with AC099580.3. The reference gene set was “Hallmark.v7.4.gmt”. CIBERSORT algorithms were used to quantify 22 immune cells in tumor tissues. The CIBERSORT reference and data source used in this study have been uploaded in Figshare (https://figshare.com/articles/dataset/CIBERSORT/16908028). Spearman’s correlation test was used to assess the correlation between AC099850.3 and immune cells. The correlation between AC099850.3 and three immune checkpoints was analyzed through the GEPIA database (http://gepia.cancer-pku.cn/index.html).

**In vivo xenograft experiments**

The protocols for animal experiments were approved by the Animal Ethics Committee of Central South University, Changsha, China. Briefly, 5 × 10^6 Huh7 cancer cells were implanted into BALB/c nude mice (n = 5 per group). All the mice received a standard laboratory diet for four weeks. Afterward, the mice were euthanized and tumor tissues were harvested. The tumor sizes were calculated using the following formula: Tumor volume (mm³) = (length × width²)/2.

**Immunostaining (IHC) and HE staining**

Xenograft tumors were firstly fixed in 4% paraformaldehyde and then dehydrated with ethanol. Next, tumor specimens were cut into sections with 5 um thick. The tissue sections were then subjected to the following treatments: 1. were mounted on glass microscope slides; 2. deparaffinized in xylene; 3. rehydrated in a graded alcohol series; 4. antigen repair in high temperature. Furthermore, the sections were cooled, rinsed, and endogenous peroxidases were quenched using 3% H₂O₂. Then, the sections were incubated with 5% BSA for 40min at room temperature. After that, the sections were incubated in the Ki67 antibody (1:2000; Proteintech) overnight at 4°C. Next, the sections were washed and incubated in secondary antibody for 1h at room temperature, whose staining was then visualized through EnVision system (EnVision; Dako, Glostrup, Denmark). Two pathologists independently and blindly interpreted the IHC using a semi-quantitative integration method. Detailed, the proportion of Ki67 positive cells was scored as 1 = 0~10%, 2 = 10%~25%, 3 = 50%~75%, and 4 = 75%~100%. Staining intensity was scored as 0 = no staining, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. The final IHC score was a product of two scores. Score larger than six were regarded as a high score and low when equal to or less than six. HE staining was performed using a HE Staining kit (Beyotime, China).

**Statistical analysis**

Statistical analyses were conducted using IBM SPSS Statistics for Windows v22.0 (IBM Corp., Armonk, NY, USA), GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA, USA) and R software (The R Foundation for Statistical Computing, Vienna, Austria/https://www.r-project.org). All experiments were repeated at least three times. Tests for statistical significance were two-sided, and P value ≤ 0.05 was considered significant.

**Results**

**Identification of candidate lncRNAs in HCC cells**

A total of 412 up-regulated and 4 down-regulated lncRNAs were identified based on a threshold value of |logFC|>3 and P value < 0.05 (Figure 1A). Considering the bias caused by extremely low expression values, DELs whose average values in tumor samples were > 0.1 were selected for further analysis. Among the 412 up-regulated lncRNAs, 38 lncRNAs satisfied the selection criteria (Figure 1B). Univariate and multivariate analyses were performed to identify prognosis-related DELs, and five DELs (LINC00942, CASC9, AC099850.3, ZFPM2-AS1, and LINC00665) were finally identified (Figure 1C). Among the five DELs, CASC9, ZFPM2-AS1, and LINC00665 have been reported to influence the biological behavior of liver cancer cells [11-13]. Furthermore, relatively high expression levels of AC099850.3 and LINC00665 were observed in tumor samples (Figure 2A-B). However, most tumor samples in TCGA-LIHC hardly expressed LINC00665, and its high expression in tumor tissues was probably due to several samples having extremely high values, which could lead to a significant bias in its correlation with prognosis. Therefore, lncRNA AC099850.3 was selected for subsequent analysis.

**AC099850.3 is highly expressed in HCC cells and it is correlated with worse clinical features**

The clinical features of enrolled patients were shown in Table 1. We examined the expression of AC099850.3 in eleven paired HCC samples and four HCC cell lines to verify its expression in HCC cells. Relatively high expression levels of AC099850.3 were observed in HCC tissues and cell lines based on TCGA data (Figure 2C-D). In addition, the results revealed that patients with high expression levels of
AC099850.3 tended to have a worse overall survival based on clinical information obtained from TCGA (Figure 2E; P = 0.0051). A high expression level of AC099850.3 was associated with worse clinical features, including pathological grade, clinical stage, and T classification (Figure 2F-H).

**Table 1.** The clinic parameters of enrolled patients obtained from TCGA-LIHC

| Clinical parameters | Number of patients (n) | Proportion of patients (%) |
|---------------------|------------------------|----------------------------|
| Age                 |                        |                            |
| <=60                | 180                    | 47.7                       |
| >60                 | 196                    | 51.9                       |
| Unknow              | 1                      | 0.3                        |
| Gender              |                        |                            |
| Female              | 122                    | 32.4                       |
| Male                | 255                    | 67.6                       |
| Grade               |                        |                            |
| G1                  | 55                     | 14.6                       |
| G2                  | 180                    | 47.7                       |
| G3                  | 124                    | 32.9                       |

Figure 1. Identification of AC099850.3 as a candidate gene. Notes: A: The volcano plot of TCGA-LIHC between normal and tumor group; B: Overview of 412 up-regulated lncRNAs; C: Five prognosis-related lncRNAs identified by multivariate cox analyses. Abbreviations: TCGA, The Cancer Genome Atlas

https://www.jcancer.org
Knockdown of AC099850.3 inhibits the proliferation of HCC cells

To determine the role of AC099850.3 in HCC, Hep3B and Huh7 cell lines were used to knock down AC099850.3 for their highest AC099850.3 expression level. qRT-PCR revealed that AC099850.3-siRNA2 exhibited the highest knockdown efficiency and was selected for subsequent experiments (Figure 3A-B). Colony formation assay revealed that knockdown of AC099850.3 significantly suppressed the proliferation ability of HCC cells (Figure 3C), which was also validated by the CCK-8 assay (Figure 3D-E). Moreover, EdU assay revealed that the knockdown of AC099850.3 reduced the level of EdU-positive cells, which suggests that it inhibits cell proliferation (Figure 3F). Also, flow cytometry results revealed that apoptosis rate in the si-AC099850.3 group increased significantly when compared with that of the control group (Figure 3G). Moreover, the results of in vivo experiments revealed that the mice implanted with si-AC099850.3 cells tended to have smaller tumors (Figure 3H). HE staining showed that the tumor with si-AC099850.3 had a lower section area than the control group (Figure 3I). In parallel, Ki67 staining revealed that the silencing of AC099850.3 reduced Ki67 positive cells in xenograft tumors (Figure 3J-K).

Knockdown of AC099850.3 suppresses the invasion and migration of HCC cells

The correlation between AC099850.3 and cell metastasis was determined. Transwell assay revealed that knockdown of AC099850.3 decreased the number of invasive and migratory cells significantly (Figure 4A-B). Similarly, the wound healing assay revealed that wound healing area in the AC099850.3
The knockdown group was smaller than that of the control group after 24 hours (Figure 4C).

**Figure 3.** AC099850.3 promotes cell proliferation in HCC. **Abbreviations:** A-B: The knockdown efficiency of AC099850.3 validated by qRT-PCR relative to GAPDH; C: Colony information assay performed in NC and si-AC099850.3 group; D-E: CCK8 assay performed in NC and si-AC099850.3 group; F: Edu assay performed in NC and si-AC099850.3 group; G: Flow cytometry detected cell apoptosis in NC and si-AC099850.3 group; H: In vivo experiment of NC and si-AC099850.3 group; I: HE staining of the xenograft tumors; J-K: Ki67 staining of the xenograft tumors. **Notes:** All experiments were repeated at least three times.
AC099850.3 facilitates cell metastasis potential in HCC. Notes: A-B: Downregulation of AC099850.3 reduced the number of invasion and migration cells in the transwell assay; C: Wound-healing assay performed between NC and si-AC099850.3 group. Notes: All experiments were repeated at least three times.

AC099850.3 activates PI3K/AKT signaling pathway

The results of GSEA revealed that the PI3K/AKT signaling pathway was associated with the biological function of AC099850.3 (Figure 5A). Consequently, the key molecules involved in the PI3K/AKT signaling pathway were analyzed by western blotting (AKT, p-AKT, and cyclin D1). The results revealed that the knockdown of AC0998503 decreased the protein levels of p-AKT and cyclin D1, implying that AC099850.3 could activate the AKT signaling pathway (Figure 5B). The results suggest that AC099850.3 promotes malignant biological behavior of HCC cells by regulating the AKT signaling pathway.

PRR11 is a target gene of AC099850.3

PRR11 exhibited a strong positive correlation with AC099850.3 based on the analysis of transcription profiling data obtained from the TCGA-LIHC database (Figure 6A, r = 0.928, P < 0.0001). PRR11 has been reported to promote the progression of liver cancer, and Kaplan–Meier survival curve analysis revealed that the PRR11 was associated with a shorter survival time (Figure 6B, P < 0.01). Therefore, we hypothesized that the oncogenic effect of AC099850.3 could be partially associated with PRR11. Subsequently, we detected PRR11 expression levels in control and si-AC099850.3 cells. The results revealed a considerable decrease in PRR11 mRNA expression levels in the AC099850.3 knockdown group (Figure 6C). The expression of PRR11 in AC099850.3-knockdown cells was restored and the overexpressed efficiency was validated using qRT-PCR assays (Figure 6D). Transwell assay revealed that the overexpression of PRR11 antagonized the anticancer effect caused by down-regulation of AC099850.3 (Figure 6E). A similar trend was also observed in the colony formation assay (Figure 6F). In addition, previous studies revealed that PRR11 could promote activation of the PI3K/AKT pathway [14]. Variations in the expression of PI3K/AKT marker in AC099850.3-knockdown cells with PRR11 re-expression were analyzed considering the PI3K/AKT pathway was the downstream effector of AC099850.3. Western blotting assay revealed that the protein levels of p-AKT and cyclin D1 were up-regulated in AC099850.3-knockdown cells after restoration of PRR11 expression (Figure 6G-1). Overall, the results of the current study revealed that AC099850.3 exerted oncogenic effects in liver cancer cells through the PRR11/PI3K/AKT pathway.

AC099850.3 act as an immune-related gene in HCC

The interaction between the immune microenvironment and tumor cells influences tumor development. Therefore, we investigated the underlying association between AC099850.3 and tumor immune microenvironment. Immune infiltration analyses results revealed that AC099850.3 was positively correlated with T follicular helper cells, M0 macrophages, CD4+ memory T cells, memory B cells, and T regulatory cells, and negatively correlated with CD8+ T cells and natural killer cells.
but negatively correlated with M2 macrophages, monocytes, natural killer (NK) cells, and CD8+ T cells (Figure 7A). Immune checkpoint therapy has been a promising field of cancer treatment. In addition, we determined the correlation between AC099850.3 and immune checkpoints. Strikingly, a significantly positive correlation was observed between AC099850.3 and four major checkpoint proteins, PD-L1 (R = 0.16, P < 0.01), PD-1 (R = 0.4, P < 0.01), CTLA4 (R = 0.28, P < 0.01), and PD-L2 (R = 0.28, P < 0.01) (Figure 7B). M2 macrophages exhibited the highest negative correlation with AC099850.3 and were therefore selected for further validation. Immunofluorescence results revealed that the tissues with high expression of AC099850.3 tended to have relatively low M2 macrophage infiltration levels (Figure 7C). Furthermore, we validated the correlation between AC099850.3 through PCR assay. The result showed that PD-1, PD-L1, CTLA4, and PD-L2 might positively correlate with AC099850.3 based on 31 liver cancer tissue (Figure 7D, PDCD1: r = 0.341, P = 0.012; CD274: r = 0.239, P = 0.04; CTLA4: r = 0.314, P = 0.006; PDCD1LG2: r = 0.159, P = 0.16).

Discussion

Liver cancer is a malignancy with high lethality globally and the most prevalent pathologic subtype of HCC [15]. The incidence of obesity, type 2 diabetes, nonalcoholic fatty, and other related liver diseases has been increasing steadily due to lifestyle changes, leading to an increased burden of liver cancer [16]. Consequently, liver cancer has been a critical public health problem worldwide; therefore, it is crucial to identify novel diagnostic biomarkers and therapeutic targets of liver cancer.

To the best of our knowledge, this is the first study to investigate the biological role of the IncRNA AC099850.3 in HCC. In the present study, IncRNA AC099850.3 was first identified as the candidate gene. Further analysis revealed that AC099850.3 was correlated with poor prognosis and clinical features. A relatively high expression level of AC099850.3 was observed in HCC tissues and cell lines. In vitro experiments revealed that the knockdown of AC099850.3 significantly impaired the proliferation and invasion ability of HCC cells. The knockdown of AC099850.3 inhibited HCC growth in vivo. Furthermore, flow cytometry revealed that a low expression level of AC099850.3 could enhance cell apoptosis.
Figure 6. PRR11 is a downstream gene of AC099850.3. Notes: A: PRR11 is significantly positive with AC099850.3; B: Kaplan-Meier survival curves showed that patients with high IGGL2-AS1 tend to have a worse prognosis; C: PRR11 expression level in NC and si-AC099850.3 cells; D: PRR11 expression level in si-AC099850.3 and si-AC099850.3+PRR11-OE cells; E: Transwell assay was performed in the NC, si-AC099850.3 and si-AC099850.3+PRR11-OE cells; F: Colony formation assay was performed in the NC, si-AC099850.3 and si-AC099850.3+PRR11-OE cells; G: The protein level of the key biomarker in PI3K/AKT pathway in NC, si-AC099850.3 and si-AC099850.3+PRR11-OE cells. Notes: All experiments were repeated at least three times.
Numerous previous studies have reported the role of AC099850.3 in cancer. For example, Zhou and colleagues revealed that the lncRNA AC099850.3 was associated with the prognosis of tongue squamous cell carcinoma and the mechanism of competing endogenous RNAs [17]. Jiang and colleagues revealed that AC099850.3 was correlated with cell autophagy and could predict the overall survival of patients with oral and oropharyngeal squamous cell carcinoma [18]. Additionally, Jia and colleagues revealed the prognostic association of AC099850.3 in HCC through bioinformatics analysis [19]. The present study initially investigated the biological function of AC099850.3 in HCC by performing a series of cell phenotyping experiments. The lncRNA AC099850.3 can promote the malignant behavior of HCC cells, in turn, serving as a potential therapeutic target.

The PI3K/AKT signaling pathway has been reported to perform essential functions in cancer progression. For instance, Blattner et al. revealed that speckle-type POZ protein mutation could facilitate tumor metastasis by modulating PI3K/AKT and AR signaling [20]. Narayankutty comprehensively reviewed preclinical and clinical evidence, and concluded that the PI3K/AKT pathway was a potential therapeutic target for colorectal cancer [21]. Moreover, drugs targeting PI3K/AKT pathway, including pan-PI3K inhibitors and isoform-specific inhibitors, have achieved satisfactory tumor treatment efficacy [22]. Ippen and colleagues assessed the efficacy of GDC-0084, a dual PI3K/AKT pathway inhibitor in breast cancer using in vitro and in vivo models, and the results revealed that GDC-0084 was a potential treatment option, especially for patients with brain metastases [23]. Also, Tarantelli et al. revealed that the novel dual PI3K/AKT inhibitor, PQR309 exhibited preclinical antitumor activity in lymphomas, and could be developed further for
lymphoma therapy [24]. Our results revealed that AC099850.3 could partially act as an oncogene depending on the PI3K/AKT pathway. Considering the critical role of the PI3K/AKT pathway in cancer, the results of the current study suggest that AC099850.3 could be a potential therapeutic target for liver cancer.

Analyses of immune cells revealed a negative correlation between AC099850.3 and NK cells and CD8+ T cells, which could be attributed to the cancer-promoting effect of AC099850.3. NK cells are abundant in healthy liver tissues and play a crucial role in the surveillance of HCC [25]. NK cells have been reported to exhibit considerable cytotoxic effects associated with cell apoptosis and patient survival [26, 27]. Generally, a high abundance of CD8+ T cells in tumor tissues results in a better prognosis of patients [28]. Previous studies have demonstrated that the inhibition of CD8+ T cells attenuates tumor-specific immune response, thereby affecting proliferation and metastasis [29]. In addition, a positive correlation was observed between AC099850.3 and the main immune checkpoint molecules (CTLA4, PD-1, PD-L1, and PD-L2). Immune checkpoint inhibitors are a novel and promising targets of tumor therapy [30]. The lncRNA AC099850.3 could be a potential novel immune-therapeutic target for HCC due to its significant association with HCC tumor immune microenvironment.

Conclusion

The present study revealed that the lncRNA AC099850.3 was up-regulated in HCC tissues and its high expression was associated with poor prognosis of patients with HCC. The lncRNA AC099850.3 significantly increased the proliferation and invasion ability of HCC cells through the PRR11/PI3K/AKT pathway. Moreover, lncRNA AC099850.3 influenced the abundance of various immune cells in the tumor microenvironment, especially M2 macrophage infiltration and was positively correlated with immune checkpoint molecules (PD-1, PD-L1, PD-L2, and CTLA4). The lncRNA AC099850.3 could be a potential therapeutic target for HCC.

Abbreviations

HCC: hepatocellular carcinoma; TCGA: The Cancer Genome Atlas; GSEA: gene set enrichment analysis; LIHC: liver hepatocellular carcinoma; LncRNA: long non-coding RNA.

Acknowledgments

Author contributions

Z.F. and L.S. performed the experiments. Z.F. wrote the manuscript. All the authors participated in the data analysis and approved the final version of the manuscript.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Yang WS, Zeng XF, Liu NZ, Zhao QH, Tan YT, Gao J, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. The British journal of nutrition. 2020; 124: 330-40.
2. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. Journal of hepatology. 2015; 62: SI44-56.
3. Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, et al. Risk of HCC. With Hepatitis B Viremia Among HIV/HBV-Infected Persons in North America. Hepatology (Baltimore, Md). 2021; 74: 1190-202.
4. Villanueva A. Hepatocellular Carcinoma. The New England journal of medicine. 2019; 380: 1450-62.
5. Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer letters. 2016; 379: 191-7.
6. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172: 393-407.
7. St Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends in genetics : TIG. 2015; 31: 239-51.
8. Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A Novel IncRNA, LINC00460, Affects Cell Proliferation and Apoptosis by Regulating KLF2 and CUL4A Expression in Colorctal Cancer. Molecular therapy Nucleic acids. 2018; 12: 684-97.
9. Li W, Dong X, He C, Tan G, Li Z, Zhao B, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Journal of experimental & clinical cancer research : CR. 2019; 38: 183.
10. Zhou Y, Huan L, Wu Y, Bao C, Chen B, Wang L, et al. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer letters. 2020; 469: 399-409.
11. Klingenberg, M, Grof M, Goyal A, Polycarpou-Schwarz M, Miensch T, Ernst AS, et al. The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling. Hepatology (Baltimore, Md). 2018; 68: 1817-52.
12. He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H, et al. Long noncoding RNA ZFP52-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/CD8F1 in hepatocellular carcinoma. Journal of experimental & clinical cancer research : CR. 2020; 39: 159.
13. Shan Y, Li P. Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei medical journal. 2019; 60: 842-53.
14. Lee KM, Guerrero-Zotano AL, Servetto A, Sudhan DR, Lin CC, Formisano L, et al. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature communications. 2020; 11: 5488.
15. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et biophysica acta Reviews on cancer. 2020; 1837: 188314.
16. Center MM, Jamal A. International trends in liver cancer incidence rates. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011; 20: 2362-8.
17. Zhou RS, Zhang EX, Sun QF, Ye ZJ, Liu JW, Zhou DH, et al. Integrated analysis of IncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue. BMC cancer. 2019; 19: 779.
18. Jiang Q, Xue D, Shi F, Qiu J. Prognostic significance of an autophagy-related long non-coding RNA signature in patients with oral and oropharyngeal squamous cell carcinoma. Oncol Lett. 2021; 21: 29.
19. Jia Y, Chen Y, Liu J. Prognosis-Predictive Signature and Nomogram Based on Autophagy-Related Long Non-coding RNAs for Hepatocellular Carcinoma. Frontiers in genetics. 2020; 11: 608668.

20. Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer cell. 2017; 31: 436-51.

21. Narayanan Kattu A. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. Current drug targets. 2019; 20: 1217-26.

22. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular cancer. 2019; 18: 26.

23. Ippey FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, et al. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019; 25: 3374-83.

24. Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, et al. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24: 120-9.

25. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clinical immunology (Orlando, Fla). 2008; 129: 428-37.

26. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012; 61: 427-38.

27. Ehrman T, Tow C, Teo M, Wong HL, Chan J, Gehring A, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. Journal of hepatology. 2010; 52: 370-9.

28. van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nature reviews Cancer. 2020; 20: 218-32.

29. Ahrends T, Borst J. The opposing roles of CD4(+) T cells in anti-tumour immunity. Immunology. 2018; 154: 582-92.

30. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature reviews Clinical oncology. 2020; 17: 725-41.

https://www.jcancer.org